Bifogade filer
Magnasense AB receives decision on penalty fee from the Swedish Financial Supervisory Authority
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
The Swedish Financial Supervisory Authority (“SFSA”) has decided to impose a fine of SEK 12 million on Magnasense AB (“Magnasense” or the “Company”) for violations of MAR.
On 14 April 2023, the SFSA started an investigation into the Company’s handling of inside information. The investigation has now been completed and the SFSA has found that Magnasense on multiple occasions has violated article 17.1 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (“MAR”) in connection with the Company’s disclosures of information to the market during the period 4 May 2021 up until 27 October 2021. The SFSA's decision means that the Company shall pay a penalty fee of SEK 12 million.
For additional information, please contact:
Marco Witteveen, CEO
Email: ir@magnasense.com
The Company’s Certified Adviser is Eminova Fondkommission AB | info@eminova.se
About Magnasense AB
Magnasense is a Swedish diagnostics company founded in 2019 to offer tests to monitor and optimize the dosage of biological drugs via its unique patented technology platform. In June 2020, Magnasense was listed on the Nasdaq First North Growth Market. The company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and to provide accurate and easily transferable results. For more information, see Magnasense's website www.magnasense.com.
The company's Certified Adviser is Eminova Fondkommission AB | 08-684 211 10 | adviser@eminova.se